Metabolic syndrome is independently associated with improved overall survival to first-line therapy with immune checkpoint inhibitors in non-small cell lung cancer
暂无分享,去创建一个
S. Graziano | Seah H. Lim | Farzam Khokhar | P. Ashok Kumar | J. Leibovitch | Mulham Ombada | Dayana Nasr | Stephanie Niforatos | Sandy Nasr | Myera Shahnawaz | Bhavya Poudyal | D. M. Barrios | Jenish Bhandari | M. Bou Zerdan | G. Ghelani | Binod Kc | Alanna Glidden
[1] A. Madabhushi,et al. Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer , 2022, Journal for ImmunoTherapy of Cancer.
[2] K. Takayama,et al. Impact of losing adipose tissue on outcomes from PD‐1/PD‐L1 inhibitor monotherapy in non‐small cell lung cancer , 2022, Thoracic cancer.
[3] A. Addeo,et al. Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations , 2022, Journal for ImmunoTherapy of Cancer.
[4] N. Segata,et al. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer , 2022, Nature Medicine.
[5] Qing Wang,et al. Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients , 2021, Cancer Immunology, Immunotherapy.
[6] Tatsuo Kawai,et al. Adipose Tissue Inflammation and Metabolic Dysfunction in Obesity. , 2020, American journal of physiology. Cell physiology.
[7] Y. Hu,et al. Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs) , 2020, Frontiers in Oncology.
[8] A. Rowland,et al. Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer. , 2019, JAMA oncology.
[9] S. Krähenbühl,et al. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors , 2019, Cancer Chemotherapy and Pharmacology.
[10] S. Klein,et al. Metabolically healthy obesity: facts and fantasies. , 2019, The Journal of clinical investigation.
[11] H. Yao,et al. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non–Small Cell Lung Cancer , 2019, JAMA network open.
[12] C. Mantzoros,et al. Obesity and cancer risk: Emerging biological mechanisms and perspectives. , 2019, Metabolism: clinical and experimental.
[13] S. Vesely,et al. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade , 2018, Nature Medicine.
[14] Kaushal Parikh,et al. Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors , 2018, Oncoimmunology.
[15] M. Mishaeli,et al. BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check‐Point Inhibitors , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[16] W. Willett,et al. Overall and Central Obesity and Risk of Lung Cancer: A Pooled Analysis , 2018, Journal of the National Cancer Institute.
[17] Kaushal Parikh,et al. Peripheral monocytes and neutrophils predict response to immune checkpoint inhibitors in patients with metastatic non-small cell lung cancer , 2018, Cancer Immunology, Immunotherapy.
[18] L. Zitvogel,et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] Laurence Zitvogel,et al. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors , 2018, Science.
[20] Shannon K. Boi,et al. Obesity alters immune and metabolic profiles: New insight from obese‐resistant mice on high‐fat diet , 2016, Obesity.
[21] A. Renehan,et al. The Obesity Paradox in Cancer: a Review , 2016, Current Oncology Reports.
[22] Y. Abed,et al. Obesity and inflammation: the linking mechanism and the complications , 2016, Archives of medical science : AMS.
[23] R. Gomis,et al. Akkermansia muciniphila inversely correlates with the onset of inflammation, altered adipose tissue metabolism and metabolic disorders during obesity in mice , 2015, Scientific Reports.
[24] F. Levenez,et al. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology , 2015, Gut.
[25] Marcin Gierach,et al. Correlation between Body Mass Index and Waist Circumference in Patients with Metabolic Syndrome , 2014, ISRN endocrinology.
[26] M. Lazar,et al. The Health Risk of Obesity—Better Metrics Imperative , 2013, Science.
[27] Isabel Azevedo,et al. Chronic Inflammation in Obesity and the Metabolic Syndrome , 2010, Mediators of inflammation.
[28] A. Butler,et al. Obesity accelerates thymic aging. , 2009, Blood.
[29] Paul L. Huang. A comprehensive definition for metabolic syndrome , 2009, Disease Models & Mechanisms.
[30] R. Yu,et al. Visceral Fat Accumulation Induced by a High‐fat Diet Causes the Atrophy of Mesenteric Lymph Nodes in Obese Mice , 2008, Obesity.
[31] R. D'Agostino,et al. Metabolic Syndrome as a Precursor of Cardiovascular Disease and Type 2 Diabetes Mellitus , 2005, Circulation.
[32] M Frost,et al. Facts and fantasies. , 1978, Nursing times.
[33] Robert C. Wolpert,et al. A Review of the , 1985 .